TD Cowen analyst Steve Scala raised the firm’s price target on AstraZeneca to $95 from $90 and keeps a Buy rating on the shares. The firm updated its model and raised estimates in each year through 2030 reflecting growth that is above the industry average yet we still are below management s 2030 revenue target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Conduit Pharmaceuticals signs license agreement with AstraZeneca
- AstraZeneca: Fixed-duration CALQUENCE study shows improvement in PFS for CLL
- AstraZeneca’s interim analysis of AMPLIFY trial statistically significant
- AstraZeneca (AZN) Announces Q3 Dividend: Read On for Important Dates
- AstraZeneca price target raised to 14,000 GBp from 13,000 GBp at JPMorgan